Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 385

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT* SAA Working Party

Bacigalupo, A., Hows, J., Gluckman, E., Nissen, C., Marsh, J., Van Lint, M. T., Congiu, M., De Planque, M. M., Ernst, P., McCann, S., Ragavashar, A., Frickhofen, N., Wursch, A., Marmont, A. M., Gordon‐Smith, E. C.·1988·British Journal of Haematology

Abstract

This is an analysis of 509 patients with severe aplastic anaemia (SAA) treated in Europe between 1981 and 1986; 218 patients were treated by allogeneic bone marrow transplantation (BMT) from HLA identical sibling donors and 291 with immunosuppressive therapy (IS) with antilymphocyte globulin (ALG). The overall actuarial survival was 63% after BMT and 61% after IS therapy at 6 years. All patients fulfilled the criteria of SAA; however, most patients with a neutrophil count of <0.2 × 10 9/l also had infections and haemorrhages. Therefore a further subclassification was defined by pretreatment peripheral blood neutrophil count: very severe aplastic anaemia (vSAA) (<0.2 × 10 9/l neutrophils) and moderately severe aplastic anaemia (mSAA) (0.2‐0.5 × 10 9/l neutrophils). A Cox regression analysis showed that the only significant pre‐treatment variables were a low neutrophil count (P= 0.001) and increasing age (P= 0.05). Thus it seemed reasonabie to analyse survival data after combined stratification for neutrophils (vSAA versus mSAA) and age (cut off at 20 years). BMT was superior to IS in patients with vSAA under 20 years of age (64%v.38%;P= 0.01). IS was superior to BMT in patients with mSAA aged 20 or more (82%v.62%;P= 0.002). The two treatments gave comparable results in young patients with mSAA (BMT = 58%, IS = 62%;P= 0.1), and in older patients with vSAA (BMT = 44%. IS = 43%;P= 0.06). Overall 75/218 and 87/291 patients, given BMT or IS respectively, died. The major cause of failure in BMT patients was graft rejection (n= 22) or problems associated with graft‐versus‐host disease. For ALG patients the major problem was persistence of the aplasia with haemorrhage (n= 32) or infections (n= 46). This study indicates that over 60% of patients with SAA can be successfully treated with either BMT or IS. Overall survival does not differ in the two groups, though significant differences emerge after stratification for severity of the aplasia and age.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.1988.tb02460.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 385

Metadata

Authors
Bacigalupo, A., Hows, J., Gluckman, E., Nissen, C., Marsh, J., Van Lint, M. T., Congiu, M., De Planque, M. M., Ernst, P., McCann, S., Ragavashar, A., Frickhofen, N., Wursch, A., Marmont, A. M., & Gordon‐Smith, E. C.
Venue
British Journal of Haematology
Publisher
Wiley
Published
1988-10
Volume
70
Issue
2
Pages
177-182
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2055482423
Cited by
385
References
7
FWCI
4.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT* SAA Working Party. https://app.cochat.ai/papers/10.1111/j.1365-2141.1988.tb02460.x
The paper
Bacigalupo, A., Hows, J., Gluckman, E., Nissen, C., Marsh, J., Van Lint, M. T., Congiu, M., De Planque, M. M., Ernst, P., McCann, S., Ragavashar, A., Frickhofen, N., Wursch, A., Marmont, A. M., & Gordon‐Smith, E. C. (1988). Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT* SAA Working Party. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.1988.tb02460.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.